Mosaic ImmunoEngineering (CPMV) Cash from Operations (2010 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Cash from Operations of 3550.0 for Q1 2026, up 87.8% year-over-year from 1890.35 in Q1 2025, and up 87.38% quarter-over-quarter from 28139.0 in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Cash from Operations (2010 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Cash from Operations history runs 17 years deep, the most recent figure standing at 3550.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 87.8% year-over-year to 3550.0; the TTM figure through Mar 2026 stood at 85858.0 (up 52.06% YoY), while the FY2025 annual figure was 111397.0, up 53.81% from the prior year.
- Cash from Operations for Q1 2026 stood at 3550.0, up from 28139.0 in the prior quarter.
- The five-year high for Cash from Operations was 3550.0 in Q1 2026, with the low at 189719.0 in Q1 2022.
- The 5-year median for Cash from Operations is 96720.0 (2023), against an average of 90806.0.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 88.19% in 2024, then slumped 67.89% in 2025.
- Mosaic ImmunoEngineering's Cash from Operations stood at 163492.0 in 2022, then surged by 40.84% to 96720.0 in 2023, then surged by 78.58% to 20717.0 in 2024, then slumped by 35.83% to 28139.0 in 2025, then surged by 87.38% to 3550.0 in 2026.
- Business Quant data shows CPMV's Cash from Operations at 3550.0 in Q1 2026, 28139.0 in Q4 2025, and 21822.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 728.46 Mn |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - | -3,550.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,550.00 |
| Mar 31, 2026 | -3,550.00 |
| Dec 31, 2025 | -28,139.00 |
| Dec 31, 2025 | -28,139.00 |
| Sep 30, 2025 | -21,822.00 |
| Sep 30, 2025 | -21,822.00 |
| Jun 30, 2025 | -32,347.00 |
| Jun 30, 2025 | -32,347.00 |
| Mar 31, 2025 | -29,089.00 |
| Mar 31, 2025 | -29,089.00 |
| Dec 31, 2024 | -20,717.00 |
| Dec 31, 2024 | -20,717.00 |
| Sep 30, 2024 | -12,998.00 |
| Sep 30, 2024 | -12,998.00 |
| Jun 30, 2024 | -116,305.00 |
| Jun 30, 2024 | -116,305.00 |
| Mar 31, 2024 | -91,139.00 |
| Mar 31, 2024 | -91,139.00 |
| Dec 31, 2023 | -96,720.00 |
| Dec 31, 2023 | -96,720.00 |